Recent Updates — BIXT

Bioxytran announced it has obtained an attested Free Sale Certificate for its dietary supplement A-SUQAR. This regulatory document confirms the product is lawfully manufactured and sold, serving as a prerequisite for market entry in the United Arab Emirates and the wider Gulf Cooperation Council region. The company intends to proceed with local product registration in the UAE and evaluate pathways in Saudi Arabia and Kuwait. Bioxytran operates as a biotechnology company developing galectin-targeting carbohydrate technologies.

Bioxytran reported encouraging clinical observations in the first patient treated with PLICID, an investigational galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The patient received once-weekly intravenous injections and demonstrated improved finger function and walking ability without adverse events. Bioxytran plans to pursue further clinical evaluation of PLICID in a larger population. Bioxytran is a clinical-stage biotechnology company developing innovative therapies for viral diseases, inflammatory conditions, and cancer metastasis using an AI-driven carbohydrate design platform.